TFF Pharmaceuticals expands its cGMP manufacturing capabilities with Experic

▴ TFF Pharmaceuticals expands its cGMP manufacturing capabilities with Experic
The expansion will increase TFF’s manufacturing capacity, as well as provide a third cGMP manufacturing location for the company

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announced that it has expanded its engagement with one of its Contract Manufacturing Organization (CMOs), Experic, LLC, with an agreement to install a Thin Film Freezing processing line and its associated capabilities at Experic’s cGMP facility in Cranbury, New Jersey.

Installation of TFF’s custom-designed equipment is expected to be complete in early Q2-2021. This will increase TFF’s manufacturing capacity, as well as provide a third cGMP manufacturing location for the company.

“This expansion of our manufacturing operations at Experic gives us the capability and capacity to develop and produce additional products currently in assessment with pharmaceutical company partners,” said Glenn Mattes, President and CEO of TFF Pharmaceuticals. “Experic has been a terrific partner for us because of their domain expertise in dry powder inhalation products. They also provide us with unique downstream encapsulation technology that rounds out the specialized manufacturing requirements of our dry powder inhalation therapies.”

“The entire Experic team is thrilled to be working with TFF Pharmaceuticals and supporting development and manufacturing activities using its Thin Film Freezing (TFF) technology,” said Jeffrey P. McMullen, Chairman and CEO of Experic. “We share their excitement in the continued advancement and expansion of their technology and business.”

Experic, a contract manufacturing organization (CMO) and pharmaceutical supply services company, supports every phase of a product’s life cycle from clinical to commercial scale, across a range of dosing and packaging formats, including capsule filling, powder and pellet dosing (including DPI), and autoinjectors and pen assemblies. Utilizing cutting-edge Harro Höfliger equipment in our state-of-the-art Class A GMP facility and build-to-suit suites, we manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise and customer service.

TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology. allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 per cent.

Tags : #TFFPharmaceuticals #LatestNewsonTFFPharmaceuticals27thOct #Experic #LatestNewsonExperic27thOct #LatestPharmaNews27thOct #GlennMattes #JeffreyPMcMullen #ThinFilmFreezingTechnology

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

Covid technical Advisory panel advises Karnataka health dept to be prepared for 2nd wave of COVID-19 pandemicDecember 04, 2020
Telangana reports 631 fresh cases of COVID-19December 04, 2020
Odisha crosses milestone in conducting over 6 million tests for COVID-19December 04, 2020
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary EndpointDecember 04, 2020
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene TherapyDecember 04, 2020
ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal EncephalopathyDecember 04, 2020
I2O Therapeutics receives strategic investment from Colorcon VenturesDecember 04, 2020
Study shows personalized provider navigation using machine intelligence may reduce post-surgical hospitalizations and lower costsDecember 04, 2020
Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India December 04, 2020
PharmaEngine, Inc. collaborates with Sentinel Oncology for SOL-578, a Chk1 inhibitorDecember 04, 2020
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND ApplicationDecember 04, 2020
1450 new cases of COVID-19 reported in Madhya PradeshDecember 04, 2020
COVID-19 recovery rate in country improves to 94.20 pctDecember 04, 2020
Over 11,70,000 samples tested for COVID-19 across country in last 24 hoursDecember 04, 2020
Britain to cover COVID-19 vaccine side-effects under damages schemeDecember 04, 2020
India’s Active Caseload further dips to 4.35% of Total CasesDecember 04, 2020
COVID-19 recovery rate in Bihar improves to 97.12 pctDecember 04, 2020
Gujarat records 1540 new cases of COVID-19December 04, 2020
Catalyst Biosciences receives FDA Fast track designation for subcutaneous MarzAADecember 04, 2020
AbbVie and Frontier Medicines establish global partnership for research and developmentDecember 04, 2020